Shijiazhuang Puli Pharmaceutical Co Ltd.

Primary Objective: This study used Shijiazhuang Puli Pharmaceutical Co., Ltd.'s licensed dapagliflozin and metformin extended-release tablets (I) as the test formulation and AstraZeneca AB's licensed dapagliflozin and metformin extended-release tablets (I) (trade name: Xigduo XR) as the reference formulation to conduct a bioequivalence study in healthy volunteers under fasting and fed conditions. Secondary Objective: To observe the safety of the test and reference formulations in healthy volunteers.

Primary Objective: This study used Shijiazhuang Puli Pharmaceutical Co., Ltd.'s licensed dapagliflozin metformin extended-release tablets (IV) as the test formulation and AstraZeneca AB's licensed dapagliflozin metformin extended-release tablets (IV) (trade name: Xigduo XR) as the reference formulation to conduct a human bioequivalence study under fasting and fed conditions to evaluate the bioequivalence of the test and reference formulations in healthy volunteers. Secondary Objective: To observe the safety of the test and reference formulations in healthy volunteers.

Primary objective: To use the vonoprazan fumarate tablets developed by Shijiazhuang Puli Pharmaceutical Co., Ltd. as the test preparation and the vonoprazan fumarate tablets (trade name: Walker®) licensed by Takeda Pharmaceutical Company Limited as the reference preparation, to investigate the pharmacokinetic parameters and relative bioavailability of the two preparations in the fasting and postprandial state after a single dose, and to evaluate whether the two preparations are bioequivalent. Secondary objective: To evaluate the safety of the test and reference preparations of vonoprazan fumarate tablets after a single oral dose in the fasting/postprandial state in the participants of the China Health Study.